OXFORD

TRENDS AND PERSPECTIVES

DREADD: A Chemogenetic GPCR Signaling Platform

Hu Zhu, MD; Bryan L. Roth, MD

Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC (Drs Zhu and Roth).

Correspondence: Bryan L. Roth, MD, PhD, 4072 Genetic Medicine Building, UNC Chapel Hill Medical School, Chapel Hill, NC 27514 (bryan_roth@med.unc.edu).

Abstract

Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.

Keywords: chemogenetics, GPCRs, GsD, hM3Dq, hM4Di

Introduction

G protein-coupled receptors (GPCRs) represent the largest family of membranous signaling molecules and are characterized structurally by a highly conserved seven-transmembrane domain motif (Allen and Roth, 2011; Meltzer and Roth, 2013). GPCRs recognize an incredible variety of ligands, including odorants, photons, neurotransmitters, lipids, hormones, peptides, and other small molecules, and regulate intracellular response to adapt to the ever-changing environment (Allen and Roth, 2011). Upon agonist activation, GPCRs undergo prototypical structural re-arrangements facilitating the interaction with a family of canonical heterotrimeric G-proteins (e.g., Gq, Gs, Gi, and G12/13) and G protein-independent signaling molecules (Allen and Roth, 2011). GPCR signaling modulates virtually every known physiological response (Allen and Roth, 2011)

To control GPCR signaling for neuropsychopharmacological therapeutics, "selective" agonists or antagonists are typically developed (Besnard et al., 2012; Meltzer and Roth, 2013). However, because most neuronal cells express multiple GPCRs and because most GPCRs are expressed in multiple tissues (Regard et al., 2008), it is essentially impossible to regulate a specific GPCR-signaling pathway in a selective

cell population by known pharmacological approaches. Additionally, the presence of endogenous receptor ligands and the lack of true specificity of pharmacological probes for GPCRs further confound the neuropsychopharmacological approach. To overcome these inherent problems associated with GPCR therapeutic approaches, the past two decades have seen a number of chemical-genetic approaches designed to control GPCR signaling *in vivo* (see Sternson and Roth, 2014, for recent review). Although the 'first generation' chemogenetic tools were useful from a heuristic perspective, they were not widely adapted (see Sternson and Roth, 2014, for review).

DREADD: A Useful and Robust Chemogenetic Platform

We adopted a novel strategy to discover useful chemogenetic tools utilizing directed molecular evolution in yeast. We were able to eventually evolve human muscarinic receptors to be activated by nM concentrations of the pharmacologically inert clozapine metabolite clozapine-N-oxide (CNO) and to simultaneously be insensitive to the native ligand acetylcholine (Armbruster et al.,


2007). Importantly, the engineered receptors which we dubbed DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) had minimal constitutive activity *in vitro* (Armbruster et al., 2007) and *in vivo*, even when expressed at high levels in neurons (Alexander et al., 2009; Zhu et al., 2014).

Since the initial description of DREADD technology (Armbruster et al., 2007), three DREADDs have been mostly commonly used in the neurosciences: hM3Dq, which is coupled to Gαq signaling and induces firing of neurons (Alexander et al., 2009); hM4Di, which is coupled to Gαi signaling and mediates neuronal (Armbruster et al., 2007) and synaptic silencing (Stachniak et al., 2014); and rM3Ds, which is coupled to Gαs signaling and which modulates neuronal activity (Farrell et al., 2013).

A schematic diagram for the application of DREADD technology is shown in Figure 1. The typical strategy for using DREADD technology to gain remote control over neuronal signaling is quite simple and is as follows (see Figure 1 for diagram of ways of expressing DREADDs):

- Express the DREADD in the cell-type of interest via either transgenic or viral technology
  - For virally-mediated transduction wait 2–3 weeks for expression
- Administer CNO either via parenteral or oral administration

Figure 1. Schematic diagram for the application of DREADD technology in vivo. (A) Two types of DREADD transgenic mouse models have been developed: cre-dependent and tet-dependent. DREADDs can be expressed in genetically defined cell populations after crossing with cre- or tet-off driver mouse lines. (B) Two types of DREADDs viruses were developed: cre-dependent and cre-independent. In the cre-dependent system, virus containing double-floxed inverted DREADDs are microinfused into the appropriate brain region in mice which express cell-type specific Cre drivers. DREADDs are flipped into the correct orientation and expressed after cre-mediated recombination to achieve very precise cell-type specific expression.

- Within a few minutes of CNO administration, the effect due to activation (via hM3Dq), inhibition (via hM4Di), or modulation (via GsD) of neuronal signaling occurs
- Monitor behavior and/or neuronal firing in freely-moving animals
- The effects of CNO will be negligible in animals which do not express DREADDs and profound in animals expressing DREADDs

Widespread Adoption of DREADD Technology

DREADDs have been successfully demonstrated to control individual GPCR signaling in many *in vivo* studies from yeast, drosophila, mice, rats, and—perhaps in the near future—primates (Farrell and Roth, 2012) and, as of August 2014, more than 500 publications have cited DREADD technology. In the

Table 1. Summary of Toolkit of DREADDs Technology

Expression system	Subtype of DREADDs	Vector information	Control system	Source	Publication
Transgenic mice	hM3Dq	TRE-HA-hM3Dq	Tet off	Available at Jackson Labs	Alexander et al. (2009)
		LoxP-STOP-LoxP-HA-hM3Dq-PTA-mCitrine	Cre-LoxP	Roth's lab (In validation)	
		RIPII-hM3Dq	Insulin promoter II	Wess's lab	Guettier et al. (2009)
		C-fos-hM3Dq	C-fos promoter	Mayford's lab	Garner et al. (2012)
	hM4Di	TRE-HA-hM4Di	Tet off	Available at Jackson Labs	Zhu et al. (2014)
		LoxP-STOP-LoxP-HA-hM4Di-PTA-mCitrine	Cre-LoxP	Roth's lab (In validation)	
		CAG-FRT-STOP-FRT-LoxP-mCherry-STOP-loxP-HA-hM4Di	Cre-LoxP and FLP-FRT	Dymecki's lab	Ray et al. (2011)
	rM3Ds	Adora2A-rM3Ds	Adora2A promoter	Available at Jackson Labs	Farrell et al. (2013)
		RIPII-rM3Ds	Insulin promoter II	Wess's lab	Guettier et al. (2009)
AAV virus	hM3Dq	HA-hM3Dq-IRES-mCitrine	hSyn, CaMKIIa, GFAP promoter	UNC Viral Vector Core; plasmids available via ADDGENE	
		HA-hM3Dq-mCherry	hSyn, CaMKIIa, GFAP promoter	UNC Viral Vector Core; plasmids available via ADDGENE	
		hSyn-DIO-hM3Dq-mCherry	Cre-LoxP	UNC Viral Vector Core; plasmids available via ADDGENE	Urban and Roth (in press)
	hM4Di	HA-hM4Di-IRES-mCitrine	hSyn, CaMKIIa, GFAP promoter	UNC Viral Vector Core; plasmids available via ADDGENE	
		HA-hM4Di-mCherry	hSyn, CaMKIIa, GFAP promoter	UNC Viral Vector Core; plasmids available via ADDGENE	Zhu et al. (2014)
		hSyn-DIO-hM4Di-mCherry	Cre-LoxP	UNC Viral Vector Core; plasmids available via ADDGENE	
	rM3Ds	HA-rM3Ds-IRES-mCitrine	CaMKIIa, GFAP promoter	UNC Viral Vector Core; plasmids available via ADDGENE	
		hSyn-DIO-rM3Ds-mCherry	Cre-LoxP	UNC Viral Vector Core; plasmids available via ADDGENE	
Lentivirus	hM3Dq	hM3Dq-mCherry	CMV promoter	Available directly from Roth lab	
		CMV-DIO-hM3Dq-mCherry	Cre-LoxP	Available directly from Roth lab	
	hM4Di	hM3Dq-mCherry	CMV promoter	Available directly from Roth lab	
		CMV-DIO-hM3Dq-mCherry	Cre-LoxP	Available directly from Roth lab	
HSV virus	hM4Di	ENK-hM4Di	Enk promoter	Unknown availability	Ferguson et al. (2011)
		DYN-hM4Di	Dyn promoter	Unknown availability	Ferguson et al. (2011)
CAV2 virus	hM3Dq	hSyn-DIO-rM3Ds-mCherry	Cre-LoxP	Unknown availability	Boender et al. (2014)

central nervous system (CNS), DREADDs have been shown to control neuronal activities in a variety of neurons, including glutamatergic (Alexander et al., 2009; Zhu et al., 2014), serotonergic (Ray et al., 2011), dopaminergic (Dell'Anno et al., 2014), and GABAergic neurons (Kong et al., 2012), to name but a few. DREADDs have also been used to control glial cell activity to modulate the autonomic nervous system (Agulhon et al., 2013). In periphery, DREADDs have been used to control GPCR signaling in pancreatic beta-cells (Guettier et al., 2009), hepatocytes (Li et al., 2013), and breast cancer cells (Yagi et al., 2011). As these applications have been reviewed recently we will not comment on them further here (Urban and Roth, in press).

Recent Advances in the DREADD Toolkit and DREADD Resources

Currently, a substantial collection of DREADD-based tools is available to control GPCR signaling *in vivo* (see Table 1). Three DREADD transgenic mouse lines created by the Roth lab can now be obtained from Jackson Labs (Table 1). Cre-dependent hM3Dq and hM4Di transgenic mice are in the process of validation in the Roth lab and will be made available soon to provide cell-type specific transgenic control of DREADD expression as outlined in Figure 1. Tissue-specific and cell type–specific expression of DREADDs can also be achieved by viral delivery (Krashes et al., 2011; Urban and Roth, in press). For many uses viral delivery is time-saving and yields a more precisely controlled DREADD expression. A variety of viral vectors—Cre-dependent or -independent—are listed in Table 1 and the majority of them can be obtained from UNC viral core facility (http://www.med.unc.edu/genetherapy/vectorcore/research-grade/in-stock-aav-vectors/roth). Current DREADD-based plasmids are available from ADDGENE (http://www.addgene.org/Bryan_Roth/) and as a service to DREADD users a blog is updated frequently (http://chemogenetic.blogspot.com/).

We continue to develop new chemogenetic tools and soon will be describing those which afford bidirectional control of GPCR signaling in same-cell population via different synthetic ligands. In the meantime, new derivatives of DREADDs have been developed by others which are likely to be quite useful. Thus, for example, an arrestin-biased DREADD was generated (Nakajima and Wess, 2012) and an axonal selective hM4D-neurexin variant was developed as a presynaptic silencer (Stachniak et al., 2014).

Future Directions for DREADD Technology

The GPCR superfamily continues to be one of the major targets for drug discovery, although CNS drug discovery remains slow and risky (Meltzer and Roth, 2013). Indeed, less than 5% of CNS drugs entering Phase I clinical trials are eventually approved by the FDA, and many GPCR-targeted drugs fail in Phase II and III clinical trials due to lack of clinical efficiency (Bradley et al., 2014). This raises the questions as to whether current animal models really recapitulate the physiological/pathological condition seen in human disease and whether pharmacological intervention of disease-related GPCR targets can ultimately deliver the desired therapeutic response. We suggest that DREADDs may represent a new "pre-evaluation" approach for GPCR drug discovery. For example, we can pre-evaluate whether pharmacological intervention of a given GPCR-signaling process by DREADD achieves the desired therapeutic response before starting a long and costly drug discovery process (Figure 2).

DREADDs may also represent a novel approach for combining gene therapy, tissue engineering, and synthetic biology. Indeed,


Figure 2. DREADDs represent a chemogenetic tool to modulate GPCR signaling in vivo. (A) Introducing two mutations in transmenbrane III and V of muscarinic receptors which create DREADDs receptors that can precisely control the Gq-, Gi-, or Gs-signaling pathways. (B) DREADDs technology has been successfully applied in β-cells, astrocytes, and a variety of neurons to control GPCR signaling in vivo. (C) DREADDs technology has a great potential to be used in drug discovery, gene therapy, and tissue engineering.

in an important recent study Dell'Anno et al. (2014) demonstrated robust and bidirectional remote control of DREADD-expressing dopaminergic neurons, which induced from iPSCs (Induced pluripotent stem cells), and were able to markedly enhance the beneficial effects in a mouse model of Parkinson's Disease. This represents the first demonstration of combining DREADD technology, gene therapy, and tissue engineering. Theoretically this approach could be potentiated by CRISPR (clustered regularly interspaced short palindromic repeats) technology (Hsu et al., 2014). Thus, for instance, one could envision engineering iPSCs by knocking in DREADDs into the downstream regions of disease-related GPCR targets using CRISPR. DREADDs could then be expressed at physiologically relevant levels in the correct cellular context. Following transplantation, we could then remotely control engineered iPSCs by administrating CNO, a drug-like small molecule, to potentially cure human disease.

Other applications are equally obvious—e.g., by engineering endogenous muscarinic receptors via CRISPR technology one could create mice in which endogenous muscarinic receptors are replaced by DREADDs to achieve precise control over muscarinic receptor subtype signaling. This would allow researchers to deconstruct the roles of various muscarinic receptors in neuropsychiatric disease models. Alternatively, CRISPR-based technology could be used to knock-in DREADDs into essentially any locus in the genome to achieve cell-type specific control of signaling in virtually any tissue and organ. Indeed, with the currently available tissue engineering, gene therapy, and synthetic biology tools we are limited only by our imagination in how we might adapt DREADD technology for interrogating and ultimately treating human neuropsychiatric diseases.

Acknowledgments

Statement of Interest

All of the work involving DREADD technology in the Roth lab summarized in this review has been supported by the NIH and by NARSAD. Mice expressing DREADD receptors have been licensed to Takeda Pharmaceuticals; Dr Roth has received a grant from Merck Pharmaceuticals for enhancing DREADD technology. Over the past 18 months Dr Roth has consulted for Pfizer Pharmaceuticals and RuiYi Pharmaceuticals and has received honoraria from Novartis Pharmaceuticals. DREADD technology is an open-source non-patented resource.

References

Agulhon C, Boyt KM, Xie AX, Friocourt F, Roth BL, McCarthy KD (2013) Modulation of the autonomic nervous system and behaviour by acute glial cell Gq protein-coupled receptor activation in vivo. J Physiol 591(22):5599–5609.

Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA, Nonneman RJ, Hartmann J, Moy SS, Nicolelis MA, McNamara JO, Roth BL (2009) Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63(1):27–39.

Allen JA, Roth BL (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51:117–144.

Armbruster BN, Li X, Pausch MH, Herlitze S, Roth, BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA, 104(12):5163–5168.

Besnard J, et al. (2012) Automated design of ligands to polypharmacological profiles. Nature 492:215–220.

Boender, AJ, de Jong, JW, Boekhoudt, L, Luijendijk, MC, van der Plasse, G, Adan, RA (2014) Combined use of the canine adenovirus-2 and DREADD-technology to activate specific neural pathways in vivo. PLoS One, 9(4):e95392.

Bradley SJ, Riaz SA, Tobin AB (2014) Employing novel animal models in the design of clinically efficacious GPCR ligands. Curr Opin Cell Biol 27:117–125.

Dell'Anno MT, Caiazzo M, Leo D, Dvoretskova E, Medrihan L, Colasante G, Giannelli S, Theka I, Russo G, Mus L, Pezzoli G, Gainetdinov RR, Benfenati F, Taverna S, Dityatev A, Broccoli V (2014) Remote control of induced dopaminergic neurons in parkinsonian rats. J Clin Invest, 124(7):3215–3229.

Farrell MS, Roth BL (2012) Pharmacosynthetics: Reimagining the pharmacogenetic approach. Brain Res 1511:6–20.

Farrell, MS, Pei, Y, Wan, Y, Yadav, PN, Daigle, TL, Urban, DJ, Lee, HM, Sciaky, N, Simmons, A, Nonneman, RJ, Huang, XP, Hufeisen, SJ, Guettier, JM, Moy, SS, Wess, J, Caron, MG, Calakos, N, Roth, BL (2013) A Galphas DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology, 38(5):854–862.

Ferguson, SM, Eskenazi, D, Ishikawa, M, Wanat, MJ, Phillips, PE, Dong, Y, Roth, BL, Neumaier, JF (2011) Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci, 14(1):22–24.

Garner, AR, Rowland, DC, Hwang, SY, Baumgaertel, K, Roth, BL, Kentros, C, Mayford, M (2012) Generation of a synthetic memory trace. Science, 335(6075):1513–1516.

Guettier JM, Gautam D, Scarselli M, Ruiz de Azua I, Li JH, Rosemond E, Ma X, Gonzalez FJ, Armbruster BN, Lu H, Roth BL, Wess J (2009) A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci USA 106(45):19197–19202.

Hsu PD, Lander ES, Zhang F (2014) Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 157(6):1262–1278.

Kong D, Tong Q, Ye C, Koda S, Fuller PM, Krashes MJ, Vong L, Ray RS, Olson DP, Lowell BB (2012) GABAergic RIP-Cre neurons in the arcuate nucleus selectively regulate energy expenditure. Cell 151(3):645–657.

Krashes MJ, Koda S, Ye C, Rogan SC, Adams AC, Cusher DS, Maratos-Flier E, Roth BL, Lowell BB (2011) Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest 121(4):1424–1428.

Li JH, Jain S, McMillin SM, Cui Y, Gautam D, Sakamoto W, Lu H, Jou W, McGuinness OP, Gavrilova O, Wess J (2013) A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo. Endocrinology 154(10):3539–3551.

Meltzer HY, Roth BL (2013) Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 123(12):4986–4991.

Nakajima K, Wess J (2012) Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol 82(4):575–582.

Ray RS, Corcoran AE, Brust RD, Kim JC, Richerson GB, Nattie E, Dymecki SM (2011) Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition. Science 333(6042):637–642.

Regard JB, Sato IT, Coughlin SR (2008) Anatomical profiling of G protein-coupled receptor expression. Cell 135(3):561–571.

Stachniak TJ, Ghosh A, Sternson SM (2014) Chemogenetic synaptic silencing of neural circuits localizes a hypothalamus—midbrain pathway for feeding behavior. Neuron 82(4):797–808.

Sternson, SM, Roth, BL (2014) Chemogenetic tools to interrogate brain functions. *Annual Review of Neuroscience*, 37:387–407.

Urban DJ and Roth BL (in press) DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Ann Rev Pharmacol.

Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, Gutkind JS (2011) A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal 4(191):ra60.

Zhu H, Pleil KE, Urban DJ, Moy SS, Kash TL, Roth BL (2014) Chemogenetic inactivation of ventral hippocampal glutamatergic neurons disrupts consolidation of contextual fear memory. Neuropsychop 39(8):1880–1892.